Relation of Endokan (ESM-1) Serum Levels with Patient Characteristics
and Morphological Features of Uterine Fibroids: A Case-control Study.
Abstract
Objectives: This study aimed to compare the serum endocan levels of
patients with uterine fibroids and the healthy control group. Design: A
case-control study was designed. Setting: A tertiary referential
university hospital. Population or Sample: The study was conducted with
130 women (uterine fibroid group, n= 65, control group, n= 65) aged
between 30 and 45. Methods: Serum endocan levels were determined in the
study and control groups using by ELISA method. The number of uterine
fibroids was identified, and the volume of uterine fibroids was
calculated with ellipsoid formula by ultrasonography. Main Outcome
Measures: The primary outcome parameter is serum endocan levels in
patients with uterine fibroids and healthy control groups. Secondly, it
is aimed to determine the distribution of serum endocan level of
patients according to uterine fibroid number, volume and clinical
presentation. Results: The mean serum endocan level of patient with
uterine fibroid was 145.18 ± 169.86 pg/mL, it was 88.94 ± 54.21 pg/mL in
the control group (p=0.016). According to Roc analysis, cut-off value of
endocan level for uterine fibroid was determined as ≥ 133.1 pg/mL. For
the cut-off value of 133.1 pg/mL; sensitivity was 36.92%, specificity
was 89.23%, positive predictive value was 77.40% and negative
predictive value was 58.60%. Above this cut-off value, a 4.8-fold
increased significant risk (OR) for uterine fibroid was detected.
Conclusion: Serum endocan levels were found to be higher in women with
uterine fibroids compared to the control group, so endocan may be
considered as a significant serum marker.